CTIC [NASD]
CTI BioPharma Corp.
Index- P/E- EPS (ttm)-1.22 Insider Own0.10% Shs Outstand99.83M Perf Week11.67%
Market Cap530.72M Forward P/E- EPS next Y-0.01 Insider Trans3.19% Shs Float74.15M Perf Month-2.49%
Income-117.80M PEG- EPS next Q-0.20 Inst Own56.90% Short Float12.67% Perf Quarter111.26%
Sales2.30M P/S230.75 EPS this Y-47.40% Inst Trans22.68% Short Ratio1.50 Perf Half Y93.80%
Book/sh-0.28 P/B- EPS next Y80.60% ROA-123.20% Target Price9.53 Perf Year84.65%
Cash/sh- P/C- EPS next 5Y- ROE-616.50% 52W Range1.43 - 5.76 Perf YTD89.11%
Dividend- P/FCF- EPS past 5Y10.20% ROI- 52W High-15.10% Beta1.00
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin87.90% 52W Low241.96% ATR0.48
Employees121 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)54.51 Volatility9.69% 10.58%
OptionableYes Debt/Eq- EPS Q/Q-64.70% Profit Margin- Rel Volume1.27 Prev Close4.69
ShortableYes LT Debt/Eq- EarningsMay 12 AMC Payout- Avg Volume6.28M Price4.89
Recom1.70 SMA203.52% SMA505.03% SMA20057.75% Volume749,873 Change4.26%
Aug-09-21Initiated BTIG Research Buy $7
May-06-21Initiated Stifel Buy $5.50
Jun-24-20Resumed JMP Securities Mkt Outperform $3
Mar-05-19Initiated Lake Street Buy $4
Mar-26-18Initiated Needham Buy $10
Mar-07-18Initiated JMP Securities Mkt Outperform $8
Sep-12-17Initiated Jefferies Buy $7.50
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
May-13-22 12:19PM  
May-12-22 05:45PM  
04:05PM  
May-10-22 07:00AM  
May-05-22 04:05PM  
Apr-28-22 04:05PM  
Apr-14-22 07:00AM  
Apr-06-22 04:05PM  
Mar-31-22 05:15PM  
04:01PM  
Mar-16-22 10:00AM  
Mar-02-22 04:05PM  
Feb-28-22 08:02PM  
07:18PM  
Feb-18-22 04:05PM  
Jan-06-22 04:30PM  
Dec-13-21 09:00AM  
Dec-11-21 11:59AM  
Dec-03-21 07:24AM  
Dec-02-21 04:30PM  
10:28AM  
Dec-01-21 01:41PM  
Nov-30-21 05:30PM  
Nov-29-21 07:00AM  
Nov-26-21 08:53AM  
Nov-09-21 04:05PM  
Nov-04-21 09:01AM  
Oct-14-21 04:05PM  
06:57AM  
Oct-05-21 10:05AM  
Oct-04-21 12:22PM  
Oct-01-21 04:05PM  
Sep-28-21 04:05PM  
Sep-17-21 04:05PM  
Sep-08-21 09:10PM  
Aug-26-21 04:52PM  
Aug-25-21 07:30AM  
07:00AM  
Aug-24-21 07:00AM  
Aug-07-21 10:30PM  
Aug-05-21 04:05PM  
Jul-29-21 07:00AM  
Jul-26-21 04:30PM  
Jul-09-21 12:48AM  
Jun-23-21 04:30PM  
Jun-09-21 06:45PM  
07:00AM  
Jun-02-21 12:00AM  
Jun-01-21 04:05PM  
09:33AM  
07:00AM  
May-26-21 04:30PM  
May-14-21 10:25AM  
May-12-21 08:34PM  
May-05-21 07:00AM  
Apr-21-21 11:28PM  
Apr-07-21 07:00AM  
Apr-02-21 03:54PM  
Mar-31-21 11:50PM  
04:41PM  
07:00AM  
Mar-22-21 01:00PM  
10:01AM  
Mar-17-21 04:05PM  
Mar-12-21 07:00AM  
Mar-08-21 11:18PM  
Feb-24-21 06:30PM  
Feb-10-21 11:55PM  
Jan-28-21 10:58PM  
Jan-01-21 07:04AM  
Dec-08-20 07:00AM  
Dec-06-20 12:30PM  
Dec-02-20 10:24PM  
Nov-30-20 07:00AM  
Nov-10-20 04:05PM  
02:30PM  
Nov-04-20 11:41AM  
Nov-02-20 04:05PM  
Oct-26-20 11:55PM  
Oct-13-20 07:00AM  
Oct-01-20 06:52PM  
Sep-30-20 07:45AM  
Sep-29-20 04:05PM  
Aug-06-20 04:05PM  
Jul-17-20 09:54AM  
Jul-06-20 07:47PM  
Jun-22-20 03:27PM  
Jun-01-20 04:22PM  
04:00PM  
02:22PM  
07:00AM  
May-28-20 07:00AM  
May-18-20 06:25AM  
Apr-27-20 07:00AM  
Apr-08-20 07:00AM  
Mar-27-20 07:00AM  
Mar-12-20 04:05PM  
Mar-06-20 06:48PM  
Feb-21-20 04:22PM  
Feb-14-20 07:00AM  
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Craig Adam RPresident and CEODec 02Buy1.523,5005,33713,500Dec 02 05:16 PM